Peroxisome Proliferator-activated Receptor Gamma Concentrations in Newly Diagnosed Hypertension Patients and the Metabolic Effects of Olmesartan

Basit Öğe Kaydı
dc.contributor.authorAkyurek, Omer
dc.contributor.authorAkbal, Erdem
dc.contributor.authorGunes, Fahri
dc.contributor.authorAkyurek, Nesibe
dc.date.accessioned2025-01-27T20:39:08Z
dc.date.available2025-01-27T20:39:08Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground and Aims. We undertook this study to investigate the effects of olmesartan treatment on PPAR-gamma (PPAR-gamma) concentrations and metabolic syndrome (MetS) components in hypertensive (HT) patients. Methods. The study included 46 newly diagnosed hypertensive patients and 30 healthy controls. All hypertensive patients were given 40 mg of olmesartan, and they were evaluated weekly in the first month and then twice weekly during follow-up visits. At the end of 3 months, MetS components were assessed and serum PPAR-gamma transcription factor concentrations were again measured. Results. MetS was noted in 80.4% of HT patients. Serum PPAR-gamma transcription factor concentration were significantly lower in those with HT compared with the controls (p = 0.005). PPAR-gamma concentrations of controls were 1.14-fold higher than hypertensive patients. HDL levels were significantly increased after treatment (p = 0.004), triglyceride, total cholesterol, fasting blood glucose (FBG), and LDL levels were significantly reduced (p <0.05). There was a tendency toward increased PPAR-gamma concentrations after treatment, but these were not statistically significant (p = 0.154). Conclusions. Olmesartan treatment was found to generate beneficial effects on MetS parameters in HT patients but did not produce any significant increases in serum PPAR-gamma transcription factor concentration. (C) 2014 IMSS. Published by Elsevier Inc.
dc.identifier.doi10.1016/j.arcmed.2013.12.005
dc.identifier.endpage142
dc.identifier.issn0188-4409
dc.identifier.issn1873-5487
dc.identifier.issue2
dc.identifier.pmid24480732
dc.identifier.scopus2-s2.0-84896846169
dc.identifier.scopusqualityQ1
dc.identifier.startpage138
dc.identifier.urihttps://doi.org/10.1016/j.arcmed.2013.12.005
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23869
dc.identifier.volume45
dc.identifier.wosWOS:000333139100005
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofArchives of Medical Research
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectPeroxisome proliferator-activated receptor
dc.subjectOlmesartan
dc.titlePeroxisome Proliferator-activated Receptor Gamma Concentrations in Newly Diagnosed Hypertension Patients and the Metabolic Effects of Olmesartan
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu